Skip to main
  1. Stocks
  2. Twist Bioscience Corp
  3. Forecast
TWST

TWST Stock Forecast & Price Target

TWST Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 9%

Bulls say

Twist Bioscience is viewed positively because its semiconductor-based DNA synthesis platform lowers cost and raises throughput, addressing a structural bottleneck in synthetic biology while supporting both NGS and DNA synthesis demand. Management and channel checks point to AI-enabled orders inflecting sharply, with FY26 AI-related demand expected to reach triple-digits growth and at least about $50M versus roughly $25M in FY25, while NGS is still expected to represent a majority of revenue in FY26 and return to 20%+ growth by FQ4. The outlook is further supported by conservative guidance, 75-80% gross margin leverage, Factory of the Future capacity for more than $1B in revenue, and a clear path to Adj. EBITDA breakeven in FQ4 as revenues ramp.

Bears say

Twist Bioscience is viewed negatively because its recent Eli Lilly antibody-characterization announcement appears non-exclusive and limited in strategic value, with Lilly retaining the service revenue and competitors like Ginkgo Bioworks making similar disclosures the same morning. The company also faces a crowded life sciences tools market where integrated incumbents such as Danaher, Agilent Technologies, and Roche can bundle products and pressure pricing, making it harder for Twist to defend a premium valuation. On top of that, the investment case depends on AI-driven and NGS demand staying strong while gross margins improve and expenses stay controlled; any slowdown in customer demand, competition, or operating leverage could delay profitability and compress sentiment.

TWST has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.

TWST Analyst Forecast & Price Prediction

Get the latest TWST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TWST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Twist Bioscience Corp (TWST) Forecast

Analysts have given TWST a Buy based on their latest research and market trends.

According to 11 analysts, TWST has a Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $153, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $153, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Twist Bioscience Corp (TWST)


TWST Analyst Forecast & Price Prediction

Get the latest TWST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TWST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TWST stock data and trends